Christopher B Ticknor MD

Physician

Summary

Dr. Christopher Ticknor is an accomplished psychiatrist based in San Antonio, Texas. He completed Medical School in 1982 and residency in Psychiatry in 1986 at The University of Texas Health Science Center at San Antonio. In addition to private practice, Dr. Ticknor is on the Clinical Faculty of UT Health San Antonio and UIW School of Medicine in San Antonio where he is a professor and teaches residents and fellows in Forensic Psychiatry. He is a past President of the San Antonio Psychiatric Society. Dr. Ticknor has contributed to the field of neuropsychiatry through research publications in peer-reviewed journals including the Journal of Managed Care Pharmacy and The Journal of Nervous and Mental Diseases, with his work being cited by other authors and publications numerous times. His exceptional work in Psychiatry and Forensic Psychiatry has earned him recognition as a Top MD from Texas Monthly magazine and a Super Doctor designation for over 20 years from SuperDoctors.com.

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Psychiatry, 1982 - 1986
The University of Texas Health Science Center at San AntonioClass of 1982

PubMed

1 citations
Pharmacologic considerations in treating depression: a patient-centered approach.
Christopher B. Ticknor
Journal of Managed Care Pharmacy. 2004-03-01
45 citations
Early dropouts from psychotherapy.
Paul C. Mohl, Diane Martinez, Christopher B. Ticknor, Milton Huang, Linda Cordell
The Journal of Nervous and Mental Disease. 1991-08-01
A Psychotherapy Service: Preserving a Place for Psychodynamic Teaching
Paul C. Mohl, Diane Martinez, Kenneth L. Matthews, Christopher B. Ticknor, Jane Appleby
Academic Psychiatry. 1989-03-01

Journal Articles

Efficacy of Duloxetine for the Treatment of Depression: Relationship to Most Recent Trials.
Petersen T, Perlis RH, Ticknor CB, Lohr J, Solvason HB, O’Reardon JP, Wohlreich M, et al., Psychopharmacology Bulletin 2008; 41(1)
Effectiveness and Clinical Usefulness of Electronic Agenda Setting in Psychiatric Practices: A South Texas PBRN Study
Deuter M, Martinez C, Preikschat B, Daniels J, Machuca A, Martinez M, King V, Ticknor CB, Tierney JG, et al., Journal of Psychiatric Practice, 1/2023
Depression to Remission: Achieving the Goal of Complete Symptom Resolution.
Ticknor CB, Purdue University Press, American Council on Pharmaceutical Education, 6/2003

Books/Book Chapters

Brain Injury Medicine
Chapter: Post Traumatic Stress Disorder
Cooper D, Ticknor CB, Kennedy JE.Editors: Eapen BC, Cifu DX.ElsevierEdition 1st,2020

Effectiveness and Clinical Usefulness of Electronic Agenda Setting in Psychiatric Practices:National Institutes of Health,2020–2023

Principal InvestigatorA 12 Week, Multi-Center, Open Label Study to Evaluate the Effectiveness and Safety of Donepezil HCl (Aricept) in Elderly Hispanic Patients with Mild to Moderate Alzheimer’s Disease; Eisai/Pfizer Pharmaceuticals2005 - 2006
Principal InvestigatorA Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Titration and Treatment with C-105 in Elderly Subjects with Mild Cognitive Impairment; Sention Pharmaceuticals2004 - 2005
Principal InvestigatorA Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion- Extended Release in Elderly Subjects with Major Depressive Disorder; GSK Pharmaceuticals2004 - 2005
Principal InvestigatorOpen Label treatment with Duloxetine Once-Daily Dosing for Evaluation of a Stabilization Dose in Patients with Major Depression; Eli Lilly & Company2003 - 2005
Principal InvestigatorWellbutrin-SR versus Escitalopram, and Placebo in the Treatment and Evaluation of Patients with Major Depression; GSK Pharmaceuticals2003 - 2005